

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy (Review of TA762) [ID6336]

Final Stakeholder List

Consultees	Commentators (no right to submit or
	appeal)
<u>Company</u>	General
AstraZeneca (olaparib)	All Wales Therapeutics and Toxicology
(Centre
Patient/carer groups	Allied Health Professionals Federation
Black Health Agency for Equality	Board of Community Health Councils in
Breast Cancer Now	Wales
Breast Cancer UK	 British National Formulary
Cancer Black Care	Care Quality Commission
Cancer Equality	Department of Health, Social Services
Helen Rollason Cancer Charity	and Public Safety for Northern Ireland
Independent Cancer Patients Voice	Healthcare Improvement Scotland Madicines and Use Illustrations
Macmillan Cancer Support Magning Cantrage	Medicines and Healthcare products Pagulatory Agency
Maggie's Centres Maggie Continue	Regulatory Agency National Association of Primary Care
Marie CurieMET UP UK	National Association of Primary CareNational Pharmacy Association
MET UP UK South Asian Health Foundation	NHS Confederation
Specialised Healthcare Alliance	Scottish Medicines Consortium
Tenovus Cancer Care	Welsh Government
Teriovus Garicei Gare	Welsh Health Specialised Services
Healthcare professional groups	Committee
Association of Breast Surgery	
Association of Cancer Physicians	Possible comparator companies
British Geriatrics Society	 Pfizer (talazoparib)
British Institute of Radiology	
British Psychosocial Oncology Society	Relevant research groups
British Oncology Pharmacy	Against Breast Cancer Breast Canada Lland
Association	Breast Cancer Hope Cashrana Breast Cancer Croun
British Society of Interventional	Cochrane Breast Cancer Group Cochrane LIK
Radiology	Cochrane UKGenomics England
Cancer Research UK Daylor College of Concept Prostitioners	Institute of Cancer Research
Royal College of General Practitioners Royal College of Nursing	MRC Clinical Trials Unit
Royal College of Nursing Royal College of Pathologists	National Institute for Health Research
Royal College of Physicians Poyal College of Physicians	Pro-Cancer Research Fund
Royal College of Physicians Royal College of Padiologists	1 10-0anoci rescalori and
Royal College of Radiologists	

Final stakeholder list for the evaluation of olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy (Review of TA762) [ID6336] Issue date: April 2024



Consultees	Commentators (no right to submit or appeal)
 Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Breast Cancer Group UK Clinical Pharmacy Association UK Oncology Nursing Society 	 Associated Public Health groups Public Health Wales UK Health Security Agency
Others Department of Health and Social Care NHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

Final stakeholder list for the evaluation of olaparib for treating BRCA mutation-positive HER2negative advanced breast cancer after chemotherapy (Review of TA762) [ID6336] Issue date: April 2024



All non-company commentators are invited to nominate clinical or patient experts.